ARS Pharmaceuticals saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 70 to 76.
When To Sell Stocks To Lock In Profits And Minimize Losses
This proprietary rating measures technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price performance over the trailing 52 weeks stacks up against all the other stocks in our database.
History shows that the market's biggest winners often have an RS Rating of above 80 in the early stages of their moves. See if ARS Pharmaceuticals can continue to rebound and hit that benchmark.
While now is not an ideal time to buy shares, see if the stock is able to offer and clear a proper buy point.
ARS Pharmaceuticals reported 0% EPS growth in the latest quarterly report, while sales growth came in at 3,044%.
ARS Pharmaceuticals holds the No. 234 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Incyte are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
